Amdocs Price Targets Slashed as Barclays Cuts to $92 and Stifel to $88
Barclays lowered Amdocs’ price target from $111 to $92 while maintaining an Overweight rating after Q1 results showed resilience under economic pressure. Stifel cut its target from $97 to $88 but reaffirmed a Buy rating, citing a five-year T-Mobile renewal and double-digit earnings return policy.
1. Analyst Price Target Revisions
On February 4, Barclays trimmed Amdocs’ price target from $111 to $92 while retaining an Overweight rating, and Stifel lowered its target from $97 to $88 while keeping a Buy rating, signalling tempered optimism despite resilient results.
2. Q1 Results and Economic Pressures
Amdocs reported first-quarter revenues and earnings above estimates, driven by solid subscription and services growth, though management warned that broader economic headwinds are applying pressure on its core markets.
3. T-Mobile Contract Renewal
The quarter featured a five-year renewal with T-Mobile, ending investor concerns over delays in the deal and reinforcing confidence in Amdocs’ ability to secure and maintain major strategic customer relationships.
4. Shareholder Returns Policy
Analysts highlighted Amdocs’ commitment to returning double-digit earnings to shareholders via dividends and buybacks, viewing the policy as a support mechanism for stock valuation amid moderated price targets.